AR046785A1 - Esteres de acido hidroxamico y uso farmaceutico de los mismos - Google Patents
Esteres de acido hidroxamico y uso farmaceutico de los mismosInfo
- Publication number
- AR046785A1 AR046785A1 ARP040104494A ARP040104494A AR046785A1 AR 046785 A1 AR046785 A1 AR 046785A1 AR P040104494 A ARP040104494 A AR P040104494A AR P040104494 A ARP040104494 A AR P040104494A AR 046785 A1 AR046785 A1 AR 046785A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- heteroaryl
- heterocycloalkyl
- heterocycloalkenyl
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
Compuestos de la fórmula general (1) en la cual R1 representa H o un radical hidrocarbonado saturado o insaturado recto o ramificado y/o cíclico, opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo que consiste en halógeno, hidroxilo, amino, nitro, y ciano; D representa N o C-R2; e representa N o C-R3; F representa N o C-R4; G representa N o C-R5; R2, R3, R4 y R5 son iguales o diferentes e individualmente representan H, halógeno, hidroxilo, amino, nitro, carboxi, ciano, alcoxi, alquiltio, alcoxicarbonilo, alquilcarboniloxi, alcoxicarboniloxi, alquilcarbonilo, alcoxisulfoniloxi, aminosulfonilo, alquilsulfonilamino, formilo, aminocarbonilo, alquilcarbonilamino, o un radical hidrocarbonado saturado o insaturado recto o ramificado, opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados del grupo que consiste en halógeno, hidroxilo, amino, nitro, carboxi, ciano, alcoxi, alquiltio, alcoxicarbonilo, alquilcarboniloxi, alcoxicarboniloxi, alquilcarbonilo, alcoxisulfoniloxi, aminosulfonilo, alquilsulfonilamino, formilo, aminocarbonilo y alquilcarbonilamino, o R2 y R3 o R3 y R4, o R4 y R5 conjuntamente con los átomos C a los cuales están unidos forman un anillo carbocíclico o heterocíclico de 5 o 6 miembros; W representa O, S, dos átomos de H, =CH2, =N-O-R6 o el grupo =N(R6); R6 representa H, cicloalquilo, heterocicloalquilo, heterocicloalquenilo, cicloalquenilo, arilo, heteroarilo, alquenilo, alquinilo, o alquilo, X e Y representan independientemente un radical de la fórmula -(CH2)i-NH-C(O)-(CH2)j-, -(CH2)k-C(O)-(CH2)m-, -(CH2)n-, -(CH2)p-CH=CH-(CH2)q-, -(CH2)r-O-(CH2)s-, -(CH2)t-NH-(CH2)u-, -(CH2)w-C(O)-NH-(CH2)z- donde i, j, k, m, n, p, q, r, s, t, u, w, y z son números enteros de 0-6, donde dichos radicales están opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados del grupo que consiste en R7; R7representa H, oxo, tioxo, halógeno, hidroxilo, amino, imino, nitro, carboxi, carbamoílo, ciano, cicloalquilo, alquilo, arilo, heteroarilo, heterocicloalquilo, heterocicloalquenilo, heterocicloalquil-heteroarilo, heterocicloalquilcarbonilamino, cicloalquenilo, alquenilo, alquinilo, alcoxi, alcoxiimino, alquiltio, alcoxicarbonilo, alquilcarboniloxi, alquenilcarboniloxi, alcoxicarboniloxi, alquilureido, alquiltioureido, alquilcarbonilo, alcoxisulfoniloxi, aminosulfonilo, alquilsulfonilamino, alquilsulfonilo, arilsulfonilo, formilo, aminocarbonilo, y alquilcarbonilamino, donde dicho amino, imino, cicloalquilo, alquilo, arilo, heteroarilo, heterocicloalquilo, heterocicloalquenilo, heterocicloalquil-heteroarilo, heterocicloalquilcarbonilamino, cicloalquenilo, alquenilo, alquinilo, alcoxi, alcoxiimino, alquiltio, alcoxicarbonilo, alquilcarboniloxi, alquenilcarboniloxi, alcoxicarboniloxi, alquilureido, alquiltioureido, alquilcarbonilo, alcoxisulfoniloxi, aminosulfonilo, alquilsulfonilamino, alquilsulfonilo, arilsulfonilo, aminocarbonilo y alquilcarbonilamino están opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados del grupo que consiste en H, halógeno, oxo, tioxo, hidroxilo, amino, imino, nitro, carboxi, ciano, alcoxi, alquiltio, alcoxicarbonilo, alquilcarboniloxi, alcoxicarboniloxi, alquilcarbonilo, alcoxisulfoniloxi, aminosulfonilo, alquilsulfonilamino, alquilsulfonilo, arilsulfonilo, aminocarboniloxi, heteroarilsulfonilamino, formilo, aminocarbonilo, trifluormetilo, alquilcarbonilamino, heterocicloalquilo, heterocicloalquenilo, arilo, alquiltioureido, heteroarilo, cicloalquilo, alquilo, cicloalquenilo, alquenilo, alquinilo, y alquilaminocarbonilo, B representa arilo, heteroarilo, heterocicloalquenilo, cicloalquilo, o cicloalquenilo, todos los cuales están opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados del grupo que consiste en R8; R8 representa H, halógeno, hidroxilo, amino, imino, oxo, tioxo, nitro, carboxi, ciano, alcoxi, fenoxi, alquiltio, alcoxicarbonilo, alcoxicarbamoílo, alquilcarboniloxi, alcoxicarboniloxi, alquilcarbonilo, alcoxisulfoniloxi, aminosulfonilo, arilsulfonilo, alquilsulfonilamino, formilo, aminocarbonilo, alquilureido, alquiltioureido, aminocarboniloxi, alquilcarbonilamino, heterocicloalquilcarbonilamino, heterocicloalquilo, heterocicloalquenilo, arilo, heteroarilo, alquilaminocarbonilo, y un radical hidrocarbonado saturado o insaturado recto o ramificado donde dicho amino, alcoxi, fenoxi, alquiltio, alcoxicarbonilo, alcoxicarbamoílo, alquilcarboniloxi, alcoxicarboniloxi, alquilcarbonilo, alcoxisulfoniloxi, aminosulfonilo, arilsulfonilo, alquilsulfonilamino, aminocarbonilo, alquilureido, alquiltioureido, aminocarboniloxi, alquilcarbonilamino, heterocicloalquilcarbonilamino, heterocicloalquilo, heterocicloalquenilo, arilo, heteroarilo, alquilaminocarbonilo, y un radical hidrocarbonado saturado o insaturado recto o ramificado están opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados del grupo que consiste en R7; A representa a un radical hidrocarbonado saturado o insaturado recto o ramificado y/o cíclico, un heterocicloalquilo, un heterocicloalquenilo, o un heteroarilo, todos los cuales están opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados del grupo que consiste en R9; R9 representa H, oxo, halógeno, trifluormetilo, hidroxilo, amino, nitro, carboxi, ciano, alcoxi, alquiltio, alcoxicarbonilo, alquilcarboniloxi, alcoxicarboniloxi, alquilureido, alquiltioureido, alquilcarbonilo, alcoxisulfoniloxi, aminosulfonilo, arilsulfonilo, alquilsulfonilamino, arilsulfonilamino, heteroarilsulfonilamino, alquilsulfonilo, formilo, aminocarbonilo, alquilcarbonilamino, alquilaminocarbonilo, aminocarboniloxi, heterocicloalquilo, heterocicloalquenilo, heteroarilo y un radical hidrocarbonado saturado o insaturado recto o ramificado donde dicho amino, alcoxi, alquiltio, alcoxicarbonilo, alquilcarboniloxi, alcoxicarboniloxi, alquilureido, alquiltioureido, alquilcarbonilo, alcoxisulfoniloxi, aminosulfonilo, arilsulfonilo, alquilsulfonilamino, arilsulfonilamino, heteroarilsulfonilamino, alquilsulfonilo, aminocarbonilo, alquilcarbonilamino, alquilaminocarbonilo, aminocarboniloxi, heterocicloalquilo, heterocicloalquenilo, heteroarilo y un radical hidrocarbonado saturado o insaturado recto o ramificado están opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados del grupo que consiste en R7; y sales, hidratos o solvatos de los mismos farmacéuticamente aceptables, para ser usados -solos o en combinación con uno o más de otros compuestos farmacéuticamente activos- en terapia, para tratar enfermedades asociadas con angiogénesis desregulada, tal como cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52626203P | 2003-12-03 | 2003-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046785A1 true AR046785A1 (es) | 2005-12-21 |
Family
ID=34652435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040104494A AR046785A1 (es) | 2003-12-03 | 2004-12-02 | Esteres de acido hidroxamico y uso farmaceutico de los mismos |
Country Status (20)
Country | Link |
---|---|
US (1) | US8034811B2 (es) |
EP (1) | EP1697312B1 (es) |
JP (1) | JP2007513098A (es) |
KR (1) | KR20070026337A (es) |
CN (1) | CN1906155B (es) |
AR (1) | AR046785A1 (es) |
AT (1) | ATE517081T1 (es) |
AU (1) | AU2004295022A1 (es) |
BR (1) | BRPI0417158A (es) |
CA (1) | CA2549242A1 (es) |
HK (1) | HK1098127A1 (es) |
IL (1) | IL175480A0 (es) |
MX (1) | MXPA06006210A (es) |
NO (1) | NO20062905L (es) |
NZ (1) | NZ547231A (es) |
RU (1) | RU2357952C2 (es) |
TW (1) | TW200529815A (es) |
UA (1) | UA89035C2 (es) |
WO (1) | WO2005054179A2 (es) |
ZA (1) | ZA200603873B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
US7241625B2 (en) * | 2005-06-02 | 2007-07-10 | Sumika Chemical Analysis Service, Limited | Carbonyl compound scavenger and method of quantifying carbonyl compound using the same |
WO2008061866A1 (en) * | 2006-11-20 | 2008-05-29 | Bayer Cropscience Sa | New benzamide derivatives |
US20100099710A1 (en) * | 2007-04-19 | 2010-04-22 | Lene Jensen | Src family kinase inhibitors |
DE102007022007A1 (de) * | 2007-05-08 | 2008-11-13 | Schebo Biotech Ag | Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes |
KR101523345B1 (ko) * | 2008-04-28 | 2015-05-28 | 주식회사 지엔티파마 | 재관류 손상의 치료 또는 예방용 약학 조성물 |
US8350026B2 (en) | 2008-08-27 | 2013-01-08 | Leo Pharma A/S | VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof |
DE102010007281A1 (de) * | 2010-02-08 | 2011-08-11 | EMC microcollections GmbH, 72070 | Neue Aminoalkyl-oxazol- und Aminoalkyl-thiazolcarbonsäureamide und ihre Anwendung zur Stimulation der endogenen situ Regeneration von Haarsinneszellen im Corti'schen Organ des Innenohres beim Säuger |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
RS58895B1 (sr) * | 2010-10-13 | 2019-08-30 | Medivir Ab | Farmaceutska formulacija za inhibitore histonske deacetilaze |
CN103889959A (zh) * | 2011-08-18 | 2014-06-25 | 巴斯夫欧洲公司 | 用于防治无脊椎动物害虫的氨基甲酰基甲氧基-和氨基甲酰基甲硫基-及氨基甲酰基甲基氨基苯甲酰胺 |
WO2013024170A1 (en) | 2011-08-18 | 2013-02-21 | Basf Se | Carbamoylmethoxy- and carbamoylmethylthio- and carbamoylmethylamino benzamides for combating invertebrate pests |
BR112014003595A2 (pt) | 2011-08-18 | 2017-03-01 | Basf Se | compostos, método de preparação de um composto, composição agrícola, método de combate ou controle de pestes invertebradas, métodos de proteção do crescimento de plantas e de proteção de sementes, semente, uso de um composto e método de tratamento de animal infestado |
WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
WO2014099503A1 (en) | 2012-12-20 | 2014-06-26 | Inception 2, Inc. | Triazolone compounds and uses thereof |
ES2718495T3 (es) | 2012-12-21 | 2019-07-02 | Celgene Quanticel Res Inc | Inhibidores de la histona desmetilasa |
CN103288684B (zh) * | 2013-05-03 | 2014-12-10 | 西安交通大学 | 一种具有抗肿瘤活性的联苯脲化合物及其制备方法 |
GB201312492D0 (en) * | 2013-07-12 | 2013-08-28 | Syngenta Ltd | Herbicidal compounds |
CN105579440A (zh) | 2013-09-06 | 2016-05-11 | 因森普深2公司 | 三唑酮化合物及其应用 |
CN104628663A (zh) * | 2013-11-08 | 2015-05-20 | 中山奕安泰医药科技有限公司 | 3-氯甲基-1,2,4-三唑啉-5-酮的合成方法 |
EA031200B1 (ru) | 2014-06-25 | 2018-11-30 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы гистоновой метилазы |
JP6543342B2 (ja) | 2014-08-14 | 2019-07-10 | アルハマドシャー,マモウン,エム. | 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション |
CN107098869B (zh) * | 2017-05-03 | 2019-05-10 | 贵州大学 | 含1,3,4-噁二唑基的双酰胺类化合物及其制备方法及应用 |
CN107286101B (zh) * | 2017-07-27 | 2020-04-21 | 云南大学 | 1-芳醛肟尿嘧啶及其制备方法 |
CN108314630B (zh) * | 2018-02-08 | 2020-11-06 | 广西民族大学 | 一种肟醚类衍生物及其制备方法与应用 |
CN109553585A (zh) * | 2018-12-29 | 2019-04-02 | 凯瑞斯德生化(苏州)有限公司 | 一种3-氯甲基-1,2,4-三唑啉-5-酮的合成方法 |
CN111135161A (zh) * | 2019-12-30 | 2020-05-12 | 谭竞 | 一种具有抗肿瘤活性的扛板归提取物的用途及其制备方法 |
EP4334298A1 (en) | 2021-06-14 | 2024-03-13 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3409668A (en) | 1964-11-07 | 1968-11-05 | Palazzo Giuseppe | Substituted anthranilamides and process for the preparation thereof |
DE1240873B (de) * | 1964-12-08 | 1967-05-24 | Hoechst Ag | Verfahren zur Herstellung von 4-Halogen-5-sulfamylanthranilsaeure-hydroxamiden |
SE366041B (es) * | 1970-04-20 | 1974-04-08 | Gyogyszerkutato Intezet | |
NL7314532A (es) * | 1972-10-27 | 1974-05-01 | ||
US5155110A (en) * | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
IE912956A1 (en) | 1990-09-10 | 1992-03-11 | Abbott Lab | Angiotensin ii receptor antagonists |
FR2689508B1 (fr) | 1992-04-01 | 1994-06-17 | Fournier Ind & Sante | Derives de l'imidazole, leur procede de preparation et leur application en therapeutique. |
GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
US5688795A (en) * | 1994-11-08 | 1997-11-18 | Syntex (U.S.A.) Inc. | 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine, pyrimidine and benzene derivatives as α1 -adrenoceptor antagonists |
GB9518993D0 (en) | 1995-09-16 | 1995-11-15 | Agrevo Uk Ltd | Fungicides |
AU1730497A (en) * | 1996-02-17 | 1997-09-02 | Agrevo Uk Limited | Fungicidal 1,2,4-oxadiazoles and analogues |
CN1072658C (zh) | 1996-09-30 | 2001-10-10 | 日本农药株式会社 | 双噻二唑衍生物和其盐以及农业园艺病害防治剂和其使用方法 |
CA2268953A1 (en) * | 1996-10-02 | 1998-04-09 | Du Pont Pharmaceuticals Company | 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv reverse transcriptase inhibitors and intermediates and processes for making the same |
US6235787B1 (en) | 1997-06-30 | 2001-05-22 | Hoffmann-La Roche Inc. | Hydrazine derivatives |
PT993439E (pt) | 1997-07-01 | 2004-12-31 | Warner Lambert Co | Derivados de acido 4-bromo ou 4-iodofenilaminobenzidroxamico e sua utilizacao como inibidores de mek |
US6326379B1 (en) * | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
HUP0104693A3 (en) * | 1998-12-16 | 2003-12-29 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
US6147107A (en) * | 1998-12-20 | 2000-11-14 | Virginia Commonwealth University | Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells |
DE69924641D1 (de) * | 1999-01-07 | 2005-05-12 | Warner Lambert Company Llc Mor | Behandlung von asthma anhand von mek-inhibitoren |
JP2002534446A (ja) * | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | 4′ヘテロアリールジアリールアミン |
JP2000281659A (ja) | 1999-03-30 | 2000-10-10 | Sumitomo Pharmaceut Co Ltd | チオウレア誘導体 |
GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
AU2001231710A1 (en) | 2000-02-09 | 2001-08-20 | Novartis Ag | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
BR0109188A (pt) | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
MY138097A (en) * | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
DE10021246A1 (de) | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
DE10023492A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
DE10023484A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
DE10023485A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel |
JP2002006453A (ja) | 2000-06-27 | 2002-01-09 | Konica Corp | 黒白ハロゲン化銀写真感光材料用現像剤及び処理方法 |
CN1219753C (zh) * | 2000-07-19 | 2005-09-21 | 沃尼尔·朗伯公司 | 4-碘苯氨基苯氧肟酸的氧合酯 |
CN1458921A (zh) * | 2000-08-25 | 2003-11-26 | 沃尼尔·朗伯有限责任公司 | N-芳基邻氨基苯甲酸和它们的衍生物的制备方法 |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20020147198A1 (en) * | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
JP2002322169A (ja) * | 2001-02-21 | 2002-11-08 | Sankyo Co Ltd | クロメン誘導体 |
WO2002066454A1 (en) | 2001-02-21 | 2002-08-29 | Sankyo Company, Limited | Chromene derivatives |
WO2002076496A1 (en) | 2001-03-22 | 2002-10-03 | Van Andel Institute | Anthrax lethal factor inhibits tumor growth and angiogenesis |
GB0111078D0 (en) | 2001-05-04 | 2001-06-27 | Novartis Ag | Organic compounds |
US20040254185A1 (en) | 2001-05-08 | 2004-12-16 | Alexander Ernst | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
WO2002090349A1 (de) | 2001-05-08 | 2002-11-14 | Schering Aktiengesellschaft | N-oxidanthranylamid-derivate und deren verwendung als arzneimittel |
DE50206476D1 (de) | 2001-05-08 | 2006-05-24 | Schering Ag | Cyanoanthranylamid-derivate und deren verwendung als arzneimittel |
TWI283164B (en) * | 2001-09-21 | 2007-07-01 | Du Pont | Anthranilamide arthropodicide treatment |
GB0126902D0 (en) | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
GB0126901D0 (en) | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
AU2002348791A1 (en) * | 2001-12-21 | 2003-07-09 | Warner-Lambert Company Llc | Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof |
WO2003062191A1 (en) | 2002-01-23 | 2003-07-31 | Warner-Lambert Company Llc | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
JP2004075614A (ja) | 2002-08-20 | 2004-03-11 | Sankyo Co Ltd | クロメン誘導体を含有する医薬 |
WO2004037853A2 (en) * | 2002-10-21 | 2004-05-06 | Irm Llc | Quinolones with anti-hiv activity |
PT1585743E (pt) | 2002-12-19 | 2007-07-12 | Pfizer | Compostos de 2- (1h-indazol-6-ilamin)-benzamida como inibidores de proteína-cinases úteis para o tratamento de doenças aftálmicas. |
WO2004085382A1 (ja) * | 2003-03-27 | 2004-10-07 | Kirin Beer Kabushiki Kaisha | 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬 |
-
2004
- 2004-02-12 UA UAA200607301A patent/UA89035C2/ru unknown
- 2004-12-02 EP EP04801164A patent/EP1697312B1/en active Active
- 2004-12-02 ZA ZA200603873A patent/ZA200603873B/xx unknown
- 2004-12-02 CN CN200480040898XA patent/CN1906155B/zh not_active Expired - Fee Related
- 2004-12-02 US US10/580,967 patent/US8034811B2/en not_active Expired - Fee Related
- 2004-12-02 AT AT04801164T patent/ATE517081T1/de not_active IP Right Cessation
- 2004-12-02 KR KR1020067010826A patent/KR20070026337A/ko not_active Application Discontinuation
- 2004-12-02 WO PCT/DK2004/000840 patent/WO2005054179A2/en active Application Filing
- 2004-12-02 RU RU2006123459/04A patent/RU2357952C2/ru not_active IP Right Cessation
- 2004-12-02 TW TW093137194A patent/TW200529815A/zh unknown
- 2004-12-02 AU AU2004295022A patent/AU2004295022A1/en not_active Abandoned
- 2004-12-02 JP JP2006541802A patent/JP2007513098A/ja active Pending
- 2004-12-02 AR ARP040104494A patent/AR046785A1/es not_active Application Discontinuation
- 2004-12-02 NZ NZ547231A patent/NZ547231A/en unknown
- 2004-12-02 BR BRPI0417158-6A patent/BRPI0417158A/pt not_active IP Right Cessation
- 2004-12-02 CA CA002549242A patent/CA2549242A1/en not_active Abandoned
- 2004-12-02 MX MXPA06006210A patent/MXPA06006210A/es active IP Right Grant
-
2006
- 2006-05-08 IL IL175480A patent/IL175480A0/en unknown
- 2006-06-21 NO NO20062905A patent/NO20062905L/no not_active Application Discontinuation
-
2007
- 2007-04-30 HK HK07104581.0A patent/HK1098127A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW200529815A (en) | 2005-09-16 |
CA2549242A1 (en) | 2005-06-16 |
NZ547231A (en) | 2010-02-26 |
WO2005054179A2 (en) | 2005-06-16 |
KR20070026337A (ko) | 2007-03-08 |
IL175480A0 (en) | 2006-09-05 |
HK1098127A1 (en) | 2007-07-13 |
CN1906155B (zh) | 2010-06-23 |
RU2357952C2 (ru) | 2009-06-10 |
NO20062905L (no) | 2006-06-21 |
US20070244117A1 (en) | 2007-10-18 |
WO2005054179A3 (en) | 2005-08-04 |
EP1697312B1 (en) | 2011-07-20 |
UA89035C2 (ru) | 2009-12-25 |
ATE517081T1 (de) | 2011-08-15 |
EP1697312A2 (en) | 2006-09-06 |
US8034811B2 (en) | 2011-10-11 |
BRPI0417158A (pt) | 2007-03-06 |
CN1906155A (zh) | 2007-01-31 |
AU2004295022A1 (en) | 2005-06-16 |
MXPA06006210A (es) | 2006-08-25 |
JP2007513098A (ja) | 2007-05-24 |
RU2006123459A (ru) | 2008-01-10 |
ZA200603873B (en) | 2008-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR046785A1 (es) | Esteres de acido hidroxamico y uso farmaceutico de los mismos | |
AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
AR117163A2 (es) | Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus métodos y usos | |
PE20230238A1 (es) | Inhibidores de kras g12c | |
CO5580767A2 (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso | |
AR054799A1 (es) | Derivados de oxindol | |
AR053712A1 (es) | Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide) | |
NO20062633L (no) | Pyrazolderivater som proteinkinasemodulatorer | |
ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
AR048669A1 (es) | Derivados biciclicos de bisamida | |
WO2006136837A3 (en) | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators | |
AR040400A1 (es) | Tratamiento de enfermedades mediadas por quimiocinas | |
AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
AR062503A1 (es) | Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor. | |
PA8575401A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso | |
AR066020A1 (es) | Derivados de imidazolidin-2, 4-diona, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de parp-1. | |
PE20161035A1 (es) | Compuestos y usos de estos para la modulacion de la hemoglobina | |
AR033525A1 (es) | Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento | |
DE602005023544D1 (de) | Angiogeneseinhibitoren | |
ECSP099335A (es) | Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos | |
PA8582801A1 (es) | Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa | |
EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |